Interleukin-10 gene therapy - Amsterdam Molecular Therapeutics

Drug Profile

Interleukin-10 gene therapy - Amsterdam Molecular Therapeutics

Alternative Names: Crohn's disease gene therapy; IL-10 gene therapy; Interleukin-10 gene therapy - AMT

Latest Information Update: 16 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Class Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Interleukin 10 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 24 Mar 2006 No development reported - Preclinical for Crohn's disease in Netherlands (unspecified route)
  • 20 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 04 Sep 2002 Preclinical trials in Crohn's disease in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top